Investor Alert: Pomerantz Law Firm Investigates Ionis Pharmaceuticals for Potential Securities Fraud
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and certain of its officers and directors on behalf of investors. The investigation follows the company's July 9, 2026 announcement that its late-stage Phase-3 CARDIO-TTransform trial for Wainua—an amyloid cardiomyopathy treatment developed with AstraZeneca—did not meet its primary endpoint. On this news, Ionis’s stock price dropped $20.19 per share (or 23.9%) to close at $64.27 on July 9, 2026. Pomerantz LLP is a leading firm in corporate and securities litigation with offices across the U.S., London, Paris, and Tel Aviv.
Topics: clinical trial failure legal action stock price drop